Jasper Therapeutics
JSPR
76 hedge funds and large institutions have $275M invested in Jasper Therapeutics in 2024 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 23 increasing their positions, 19 reducing their positions, and 13 closing their positions.
141% more call options, than puts
Call options by funds: $3.39M | Put options by funds: $1.4M
54% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 13
21% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 19
10% more funds holding
Funds holding: 69 → 76 (+7)
0.67% more ownership
Funds ownership: 96.52% → 97.19% (+0.67%)
4% less capital inflows, than outflows
Capital inflows: $47.4M | Capital outflows: $49.3M
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Braidwell
Stamford,
Connecticut
|
+$9.6M |
| 2 |
Integral Health Asset Management
New York
|
+$6.97M |
| 3 |
Morgan Stanley
New York
|
+$5.1M |
| 4 |
Ally Bridge Group
New York
|
+$3.6M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$2.82M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Avidity Partners Management
Dallas,
Texas
|
-$17.8M |
| 2 |
Octagon Capital Advisors
New York
|
-$6.53M |
| 3 |
Sphera Funds Management
Tel Aviv,
Israel
|
-$5.28M |
| 4 |
Stempoint Capital
New York
|
-$3.26M |
| 5 |
Silverarc Capital Management
Boston,
Massachusetts
|
-$2.49M |
JSPR Hedge Fund Activity: Q3 2024 in Review
76 of the 6,989 institutional investors tracked by Wall St. Rank reported a position in Jasper Therapeutics (JSPR) for Q3 2024, worth a combined $275M — down 17% from $330M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new JSPR positions and 13 closed out — a net gain of 7 holders — while 23 added to existing stakes and 19 trimmed.
The largest buyer was Braidwell, opening a new position worth an estimated $9.6M. The largest seller was Avidity Partners Management, exiting entirely with an estimated $17.8M sold.
- 76 institutional investors held Jasper Therapeutics (JSPR) as of Q3 2024, up from 69 in Q2 2024.
- Funds reported $275M of Jasper Therapeutics stock for Q3 2024, down 17% quarter-over-quarter.
- 20 funds opened new Jasper Therapeutics positions in Q3 2024 and 13 closed out, a net change of +7 holders.
- The largest Jasper Therapeutics buyer in Q3 2024 was Braidwell, an estimated $9.6M added.
- The largest Jasper Therapeutics seller in Q3 2024 was Avidity Partners Management, an estimated $17.8M sold.
Based on aggregated 13F filings for Q3 2024.